Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients

Quillien, V; Lavenu, A; Ducray, F; Meyronet, D; Chinot, O; Fina, F; Sanson, M; Carpentier, C; Karayan-Tapon, L; Rivet, P; Entz-Werle, N; Legrain, M; Zalcman, EL; Levallet, G; Escande, F; Ramirez, C; Chiforeanu, D; Vauleon, E; Figarella-Branger, D

Quillien, V (reprint author), Ctr Eugene Marquis, F-35042 Rennes, France.

CANCER BIOMARKERS, 2017; 20 (4): 435

Abstract

BACKGROUND: Pyrosequencing is recognized as a strong technique to analyze the MGMT status of glioblastoma patients. The most commonly used assay, quan......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索